182 related articles for article (PubMed ID: 276348)
1. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
Morton DL; Eilber FR; Holmes EC; Ramming KP
Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide.
Elias EG; Suter CM; Fabian DS
J Surg Oncol; 1997 Jan; 64(1):17-22. PubMed ID: 9040795
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
6. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
7. Results of BCG adjuvant immunotherapy for melanoma of the head and neck.
Eilber FR; Townsend CM; Morton DL
Am J Surg; 1976 Oct; 132(4):476-9. PubMed ID: 1015538
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Abdi EA; Hanson J; McPherson TA
Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
[TBL] [Abstract][Full Text] [Related]
10. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Peter HH; Deutschmann EM; Schultheis W; Deicher H
Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
[TBL] [Abstract][Full Text] [Related]
11. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunotherapy in melanoma: a new approach.
Elias EG; Tomazic VJ; Buda BS
J Surg Oncol; 1992 Jul; 50(3):144-8. PubMed ID: 1619935
[TBL] [Abstract][Full Text] [Related]
13. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
Ariyan S; Kirkwood JM; Mitchell MS; Nordlund JJ; Lerner AB; Papac RJ
Surgery; 1982 Sep; 92(3):459-63. PubMed ID: 7112396
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
15. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
16. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
18. BCG immunotherapy in patients with malignant melanoma.
Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
[TBL] [Abstract][Full Text] [Related]
19. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation].
Pawlicki M; Jońca M; Krzemieniecki K; Zuchowska-Vogelgesang B
Wiad Lek; 1993 Dec; 46(23-24):912-4. PubMed ID: 7900387
[TBL] [Abstract][Full Text] [Related]
20. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
